Jurriën M. ten Berg works in Interventional / Structural Cardiology affiliated with St. Antonius Ziekenhuis.
Jurriën M. ten Berg is Full Professor of Antithrombotic Therapy in Cardiac Catheter Interventions at Maastricht University and an interventional cardiologist at St. Antonius Hospital in Nieuwegein, the Netherlands. He heads the St. Antonius Center for Platelet Function Studies and serves as Director of the Cardiology Training Program. He received his MD from Utrecht University in 1990 and his PhD from Radboud University Nijmegen in 2001.
686 pubs · 49,003 cites · h-index 84
MD
Utrecht University
1990
PhD
Radboud University Nijmegen
2001
MSc
London School of Economics
2017
Full Professor of Antithrombotic Therapy in Cardiac Catheter Interventions
Maastricht University · 2020 - Present
Interventional Cardiologist, Head of Center for Platelet Function Studies and Director of Cardiology Training Program
St. Antonius Hospital · 1996 - Present
LancetBaumbach et al.RCT
Myval THV series offers a non-inferior TAVR option in severe aortic stenosis; extends randomized evidence for next-generation valves versus Sapien and Evolut.
JACCBrar et al.meta-analysis
Elevated on-treatment platelet reactivity on clopidogrel (particularly PRU ≥230 on the VerifyNow P2Y12 assay) strongly predicts long-term death, myocardial infarction, and stent thrombosis following percutaneous coronary intervention.
JACCSerruys et al.RCT
The novel balloon-expandable Myval THV series provides comparable 1-year clinical efficacy to established contemporary THVs in patients with severe symptomatic aortic stenosis.
Journal of Thoracic and Cardiovascular SurgeryDaeter et al.cohort
Researchers compared 1,211 patients from the DEDICATE trial of TAVI versus surgery to a Dutch surgical registry. At one year, real world surgical patients had fewer deaths or strokes than matched surgical patients in the trial. Reweighting the data shrank the absolute drop in one year deaths with TAVI from 3.7% in the trial to an estimated 2.2% in the registry population. The absolute benefit of TAVI may be smaller in everyday practice.
Cardiac Valve Diseases and Treatments · Amsterdam University Medical Centers
These findings suggest that the extent of CAD should be incorporated into decision-making for TAVR patients with concomitant coronary disease, but confirmation from randomized studies is needed
JACC: Cardiovascular InterventionsBroeze et al.
American Heart JournalOverduin et al.RCT
The POPular ACE TAVI trial is an ongoing study that will randomize 1,000 patients to routine versus selective protamine administration after TAVI. It will evaluate whether routine use cuts deaths or clinically relevant bleeding at 30 days.
President and COO, Medicure Inc.
We have received substantial feedback from physicians that there is a need for more potent antiplatelet therapy when treating STEMI patients undergoing percutaneous coronary intervention. We believe the STEMI indication would increase the utility of AGGRASTAT for physicians, and thereby increase hospital adoption and demand.
Journal of the American College of CardiologyBerg et al.
Interventional / Structural Cardiology · University College Dublin
With the rapid onset of action of the oral and intravenous P2Y12 inhibitors and the modern era of short delays between hospital admission and catheterization, the risk of an ischemic complication before catheterization is extremely low, suggesting that there is no longer a need for pre-treatment in NSTE-ACS patients to prevent ischemic complications while waiting for catheterization. Moreover, there is also no benefit of pre-treatment on peri-PCI complications. Together, our findings suggest use of prasugrel should be considered only after the coronary anatomy has been defined.
JACCMontalescot et al.RCT
The ACCOAST trial tested giving prasugrel before an angiogram against giving it at the time of the stent in NSTEMI patients. At seven days, 13.1% versus 13.1% had a heart death, heart attack, stroke, an urgent artery procedure or bailout medication. Giving the drug early increased major and life threatening bleeding. The authors conclude prasugrel should be deferred until a decision is made about a stent.
JACCTantry et al.Guideline
Standardizes platelet function test thresholds for risk stratification post-PCI; leaves open whether routine testing and tailored.
Interventional / Structural Cardiology · University of Messina
One thing we encountered in Italy was a high rate of infection among healthcare providers. Probably some hospitals, due to better organization and protection devices, [had] less contamination and this could have created more trust towards the institution
Journal of the American College of CardiologyLuca et al.
Cardiac Imaging and Diagnostics · Amsterdam Neuroscience
SVG PCI was associated with better outcomes with respect to MACE at 1-year follow-up, which was primarily driven by lower rates of PCI-related MI and clinically driven target coronary territory revascularization. Importantly, these findings apply to patients in whom both strategies are considered technically feasible by the heart team in a cohort with a high prevalence of complex native CTO lesions. These results challenge current guidelines at 1 year follow-up.
Journal of the American College of CardiologyWinter et al.
Interventional / Structural Cardiology · Maastricht University Medical Centre
TAILOR-PCI was misinterpreted. It was said to be a negative trial, and that's not correct.
The LancetGimbel et al.
JACCVerheugt et al.Original Research
May inform antithrombotic dosing to curb thrombosis while monitoring bleeding; leaves open larger confirmatory trials.
Interventional / Structural Cardiology · Erasmus MC
For the treatment of transcatheter aortic valve (TAV) thrombosis, both in its more common form of subclinical leaflet thrombosis (SLT) and the rarer clinical valve thrombosis (CVT), pharmacotherapy with vitamin K antagonists (VKA), non-vitamin K oral anticoagulants (NOAC) and an ultraslow, low-dose infusion of thrombolytics should be considered as treatment of first choice, according to a recent JACC review topic of the week.
Journal of the American College of CardiologyAdrichem et al.
JACCWerkum et al.case-control
Emphasizes early clopidogrel adherence post-PCI; leaves open causal confirmation in prospective trials.
EHJAzzahhafi et al.cohort
Genotype-guided de-escalation appears feasible in practice; leaves open whether it improves net clinical outcomes.
Interventional / Structural Cardiology · Sheffield Teaching Hospitals NHS Foundation Trust
What we found was that selatogrel rapidly inhibits platelet clotting activity within 15 minutes and its effect was very consistent across different patients and lasted for up to 8 hours. It was safe and well tolerated and its effect had worn off by 24 hours. This represents a potential solution to two problems in acute heart attack management. Firstly, it could provide a very early anticlotting effect during the critical early phase of a heart attack, reducing the damage to the heart muscle.
European Heart JournalStorey et al.
JACCErlinge et al.Cohort Study
Hypothesis-generating for prasugrel 5 mg in very elderly; leaves open effects on ischemic and bleeding events.
JACCErlinge et al.Clinical Trial
May support reduced-dose prasugrel in low-body-weight patients; leaves open effects on clinical ischemic and bleeding events.
Future CardiologyVoorhout et al.Review
Review highlights interaction between metabolic risk factors and cardiovascular events in atrial fibrillation and CAD, suggesting integrated management strategies.
